PDCD1 and cancer: In addition, the combined inhibition of TIM-3 or LAG-3 with anti-PD-1/PD-L1 mAb could provide better therapeutic means for enhancing Teff activity, targeting Treg function and overcoming resistance, thereby maximizing the efficacy of current cancer therapies.